François Ravenelle, PhD
Founder & CEO
Dr. Ravenelle is championing the comeback of cannabinoid receptor-1 (CB1) blockers at Inversago Pharma Inc.
An entrepreneur with 16 years of industrial R&D experience, his background includes pharmaceutical development from discovery through NDA approval.
Christine McCarthy, MD
Acting Chief Medical Officer
Dr. McCarthy oversaw clinical development programs at Sanofi, including worldwide responsibility for rimonabant’s large Phase III program.
Christine has more than 25 years of experience in large pharma companies.
Jean-Marie Vallet, PhD, MBA
Acting Chief Business Development Officer
Dr. Vallet has over 30 years of experience in the pharma/biotech industry acquired across several functional areas, including Research, Business Development / Licensing, Strategic Planning, Corporate M&A and Finance & Administration.